Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin

C. S. Karyekar, R. Frederich, S. Ravichandran

SUMMARY

Background: In four 24-week controlled studies, the antihyperglycaemic efficacy of saxagliptin was demonstrated in patients with type 2 diabetes mellitus as add-on therapy to glyburide, a thiazolidinedione, or metformin, and when used in initial combination with metformin vs. metformin monotherapy in drug-naive patients.

Methods: Data from these studies were analysed to compare the proportions of patients who achieved specific reductions from baseline in glycated haemoglobin (HbA1c) reductions of ≥ 0.5% and ≥ 0.7% in all studies (prespecified); reductions ≥ 1.0% in the add-on studies and ≥ 1.0% to ≥ 2.5% in the initial combination study (post hoc) for saxagliptin vs. comparator at week 24. We report overall rates of glycaemic response defined by these reductions in HbA1c and rates of response without experiencing hypoglycaemia. Results: Large glycaemic response rates were higher with saxagliptin 2.5 and 5 mg/day than with comparator (HbA1c ≥ 1.0%, 31.7–50.3% vs. 10.3–20.0%) as add-on therapy and higher with saxagliptin 5 mg/day as initial combination with metformin than with metformin monotherapy (HbA1c ≥ 2.0%, 68.3% vs. 49.8%) in drug-naive patients. Addition of saxagliptin was associated with a low incidence of hypoglycaemia; overall response rates and response rates excluding patients who experienced hypoglycaemia were similar. Analysis of several demographic and baseline clinical variables revealed no consistent correlations with response to saxagliptin. Conclusions: Whether receiving saxagliptin as an add-on therapy to glyburide, a thiazolidinedione, or metformin, or in initial combination with metformin, a greater percentage of patients achieve clinically relevant large reductions in HbA1c vs. comparator, with a low incidence of hypoglycaemia.

What’s known
- The risk of developing complications of diabetes increases with increasing levels of glycaemia.
- Greater reductions in hyperglycaemia lower the risk of complications.

What’s new
- The proportions of patients who achieved large reductions in HbA1c (responders) were significantly higher with saxagliptin as an add-on to another antihyperglycaemic drug or in initial combination with metformin than with the comparator regimens.
- Hypoglycaemia incidence is low with saxagliptin; responder rates excluding patients who experience hypoglycaemia were also significantly higher with saxagliptin.
- Response to saxagliptin did not consistently correlate with any demographic or baseline characteristic analysed.

Introduction

Glycaemic control to a specific recommended target is an important goal in the management of type 2 diabetes mellitus (T2DM) to minimise the risk of microvascular and macrovascular complications (1–5). However, patients do not always reach the target glycated haemoglobin (HbA1c) levels (< 6.5% or < 7.0%) recommended for most patients by the American Association of Clinical Endocrinologists (AACE) (6) and the American Diabetes Association (ADA)/European Society for the Study of Diabetes (EASD) (7) with antihyperglycaemic therapy. To reduce HbA1c in T2DM, a variety of antihyperglycaemic drugs are available, utilising different mechanisms of action and offering different degrees of effectiveness and safety. Metformin is the most commonly used first-line agent and works primarily by inhibiting hepatic gluconeogenesis and enhancing skeletal muscle uptake of glucose (8,9). Insulin secretagogues, including sulphonylureas, are effective but may cause hypoglycaemia and weight gain via excessive stimulation of insulin and tend to become less effective over time (10). Thiazolidinediones (TZDs) improve glycaemic control by increasing insulin sensitivity but are associated with weight gain and oedema and increased risk of congestive heart failure (7,11). Dipeptidyl peptidase-4 (DPP-4) inhibitors are newer agents that act by stimulating glucose-dependent insulin secretion (12,13). They offer a low risk of hypoglycaemia, are not associated with weight gain (14), and fulfill the need for safe and effective antihyperglycaemic drugs.

Irrespective of the choice of therapy, reductions in HbA1c lower the risk of complications. For example, a report from the United Kingdom Prospective Diabetes Study (UKPDS) showed that each 1% decrease in HbA1c was associated with significant reductions...
 Clinically relevant reductions in HbA1c with saxagliptin

of 21% in diabetes-related deaths, 14% in myocardial infarction and 37% in microvascular complications (4). Thus, it is valuable to understand the magnitude of HbA1c reductions that might occur with antihyperglycaemic therapy, even in patients for whom reaching target HbA1c levels is challenging. Furthermore, an understanding of which patient groups may experience the greatest reduction in HbA1c levels may help guide physicians in choosing optimal treatment for patients with T2DM.

Dipeptidyl peptidase-4 inhibitors are known to provide mean reductions from baseline in HbA1c in the range of 0.5–0.8% when used as monotherapy in conjunction with diet and exercise or as combination therapy with metformin, a sulphonylurea, or a TZD (15–23). However, a subset of patients can achieve larger reductions in HbA1c. In addition, the favourable safety and tolerability profile of these agents and their oral route of administration may facilitate adherence to treatment (24). This would be anticipated to improve ‘real world’ glycaemic control. For these reasons, the AACE and ADA/EASD treatment recommendations consider DPP-4 inhibitors as one of the first-line therapies in patients in whom metformin is contraindicated, and one of the first choices in combination with metformin (7,25).

The DPP-4 inhibitor, saxagliptin, is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM (26). Randomised phase 3 trials have shown that reductions in HbA1c were significantly greater with saxagliptin 5 mg once daily vs. placebo or comparator as an add-on to metformin (16), the sulphonylurea glyburide (15), or a TZD (pioglitazone or rosiglitazone) (17); and significantly greater with saxagliptin 5 mg as initial combination with metformin vs. metformin monotherapy in drug-naive patients (18). Except for the study of add-on to the sulphonylurea, saxagliptin was not associated with an increased risk of hypoglycaemia.

In these phase 3 trials of saxagliptin, reductions from baseline in HbA1c of 0.5% and 0.7% were assessed as prespecified end-points. Understanding the potential of saxagliptin to achieve large decreases in HbA1c could be more meaningful, especially in patients who rarely achieve glycaemic targets. Therefore, a post hoc analysis of data from these trials to evaluate the ability of saxagliptin to produce clinically relevant and larger-than-prespecified mean reductions in HbA1c (≥ 1.0% in the add-on studies; ≥ 1.0% to ≥ 2.5% in the initial combination study) was conducted. As large reductions in HbA1c could potentially be associated with a higher risk of hypoglycaemia, we defined and evaluated antihyperglycaemic effects as successful when defined reductions in HbA1c were achieved without incurring hypoglycaemia. Furthermore, demographic and baseline clinical variables were examined to identify possible predictors of large glycaemic response to treatment with saxagliptin.

Methods
The methods for each of these studies have been previously published (15–18). Participants were adults aged 18–77 years with a diagnosis of T2DM and baseline HbA1c indicating inadequate glycaemic control within defined limits: 7–10% in the study of saxagliptin add-on to metformin (16), 8–12% in the study of initial combination with metformin (18), 7.5–10% in the study of saxagliptin add-on to glyburide (15) and 7–10.5% in the study of saxagliptin add-on to TZD (17). Other study entry criteria included body mass index (BMI) < 40 kg/m2 (extended to < 45 kg/m2 in the study of add-on to a TZD) and no contraindications to therapy with a DPP-4 inhibitor.

In the add-on to metformin study (16), patients receiving stable total daily doses of metformin 1500–2550 mg/day at study entry were randomly assigned to receive saxagliptin 2.5, 5, or 10 mg once daily or placebo. In the add-on studies with glyburide (15) or a TZD (17), patients were randomly assigned to receive saxagliptin 2.5 or 5 mg once daily or placebo along with continued use of the background agent (in the placebo arms, dosing was uptitrated for glyburide but kept at the regimen in use at baseline for the TZD). In the study of initial combination with metformin (18), drug-naive patients were randomly assigned to receive metformin, titrated from 500 mg/day to a target dosage of 2000 mg/day, as monotherapy or in combination with saxagliptin 5 or 10 mg once daily; patients in a fourth treatment arm received saxagliptin 10 mg once daily as monotherapy.

Analysis
For each of the studies in this analysis, the primary end-point was adjusted mean change from baseline to week 24 in HbA1c. Secondary end-points generally included adjusted mean change from baseline to week 24 in fasting plasma glucose, adjusted mean change from baseline to week 24 in postprandial glucose, and the proportion of subjects achieving HbA1c < 7%. Glycaemic response levels were also defined by specific reductions in HbA1c after 24 weeks of treatment. In the original studies, percentages of patients achieving reductions in HbA1c of ≥ 0.5% and ≥ 0.7% were prespecified as additional end-points.

The present post hoc analyses include data only from patients who received the 2.5- and 5-mg doses
of saxagliptin, which are the doses approved by the United States Food and Drug Administration and the European Union. The proportions of patients in each treatment group who achieved larger reductions in HbA1c were evaluated in each study. For the add-on studies, reductions in HbA1c of ≥ 1.0% were assessed; for the study of initial combination therapy with metformin in drug-naive patients, HbA1c reductions of ≥ 1.0%, ≥ 1.5%, ≥ 2.0% and ≥ 2.5% were assessed. More stringent criteria were used in the initial combination study because large reductions in HbA1c would be expected.

In addition to reporting overall rates of response defined by these specific reductions in HbA1c, we report response rates for patients who did not experience hypoglycaemia during treatment, counting patients who experienced one or more episodes of hypoglycaemia as non-responders. In these analyses, hypoglycaemia was based on reports of symptoms (with or without fingerstick confirmation).

For statistical analysis, last observed data were carried forward for participants who did not complete 24 weeks of treatment. Comparisons of the proportions of patients who achieved defined glycaemic response with saxagliptin vs. comparator were performed using Fisher’s exact test and 95% exact CIs for the difference in proportions were calculated.

To explore correlations between baseline characteristics and decreases in HbA1c, either overall or for a specific treatment group, logistic regression was performed, using terms for treatment group, baseline characteristic and treatment group by baseline characteristic. For each of the four studies, odds ratios for the association of achieving a specific percentage decrease in HbA1c for saxagliptin vs. comparator were calculated for 10 baseline covariates [sex, age, duration of diabetes, BMI and HbA1c as categories; and quartiles for C-peptide area under the curve (AUC), insulin AUC, glucagon AUC, glucose AUC, and insulin secretion assessed as homeostasis model assessment 2 β-cell function (HOMA2-%β)], to identify characteristics that could correlate with glycaemic response (defined for this purpose as HbA1c reduction ≥ 1% in the add-on studies and ≥ 2% in the initial combination study). Nominal p-values for the association of each baseline characteristic and baseline characteristic by treatment group with response rate were generated from the logistic analysis.

**Results**

A total of 3382 patients participated in the four clinical studies. Baseline characteristics of the study populations have been previously published (15–18). Across the four studies, mean age of participants ranged from 52 to 55 years, mean duration of diabetes ranged from 1.4 to 7.1 years and mean BMI ranged from 29 to 32 kg/m²; men and women participated in roughly equal numbers, and most of the participants were white.

**Glycaemic response**

In the three add-on studies, in which saxagliptin was given at 2.5 and 5 mg once daily (15–17), glycaemic response rates were numerically higher with the 5-mg than with the 2.5-mg dose. In this post hoc analysis, the proportions of patients achieving predetermined glycaemic responses without incurring hypoglycaemia were higher with saxagliptin 2.5 and 5 mg once daily than with comparators in each of the individual studies (Tables 1–3). In the saxagliptin add-on to metformin study (Table 1, Figure 1), the rates of response defined by HbA1c reduction ≥ 1% were 33.3% with saxagliptin 2.5 mg plus metformin and 39.8% with saxagliptin 5 mg plus metformin vs. 10.3% with placebo plus metformin [difference from placebo (95% CI) 23.0% (14.8%, 31.2%) and 29.5% (20.9%, 37.8%) for 2.5 and 5 mg, respectively]. When patients who experienced one or more hypoglycaemia events were removed from the analysis (5.2–7.8% in the saxagliptin plus metformin groups vs. 5.0% in the placebo plus metformin group), the rates of response were 29.6% for 2.5 mg and 37.1% for 5 mg vs. 9.7% for placebo [difference from placebo 19.9% (11.9%, 27.9%) and 27.4% (19.0%, 35.6%)].

In the saxagliptin add-on to the sulphonylurea glyburide study (Table 2, Figure 1), the rates of response defined by HbA1c reduction ≥ 1% were 31.7% with saxagliptin 2.5 mg plus glyburide and 36.4% with saxagliptin 5 mg plus glyburide vs. 13.6% with placebo plus uptitrated glyburide [difference from placebo 18.1% (10.9%, 25.2%) and 22.8% (15.4%, 30.0%) for 2.5 and 5 mg, respectively]. Not counting patients who experienced one or more episodes of hypoglycaemia (13.3–14.6% in the saxagliptin plus glyburide groups vs. 10.1% in the placebo plus glyburide group), the rates of response were 24.8% and 30.4% vs. 12.1% [difference from placebo 12.7% (6.0%, 19.5%) and 18.3% (11.3%, 25.3%) for 2.5 and 5 mg, respectively].

In the saxagliptin add-on to a TZD study (Table 3, Figure 1), the rates of response defined by HbA1c reduction ≥ 1% were 39.6% with saxagliptin 2.5 mg plus TZD and 50.3% with saxagliptin 5 mg plus TZD vs. 20.0% with placebo plus TZD [difference from placebo 19.6% (10.4%, 28.6%) and 30.3% (20.7%, 39.3%) for 2.5 mg and 5 mg, respectively].
Without patients who experienced one or more episodes of hypoglycaemia (2.7–4.1% in the saxagliptin plus TZD groups vs. 3.8% in the placebo plus TZD group), the rates of response were 37.5% and 48.6% vs. 19.4% [difference from placebo 18.1% (8.9%, 27.0%) and 29.2% (19.7%, 38.2%) for 2.5 mg and 5 mg, respectively].

In the analysis of initial combination therapy with saxagliptin 5 mg and metformin in drug-naive patients (Table 4, Figure 2), rates of response defined by HbA1c reduction ≥ 1.0% were 68.3% with saxagliptin plus metformin vs. 49.8% with metformin monotherapy [difference from metformin 18.5% (10.7%, 26.0%)]. Rates of response defined by HbA1c reduction ≥ 0.7% were 51.3% vs. 33.9% [difference from metformin 17.4% (9.6%, 25.1%)]. Not counting patients who experienced one or more events of hypoglycaemia (3.4% in the saxagliptin plus metformin group vs. 4.0% in the placebo plus metformin group), the rates of response defined by HbA1c reduction ≥ 2.5% were 49.3% vs. 31.6% [difference from metformin 17.7% (10.0%, 25.2%)].

**Correlation between baseline characteristics and glycaemic response**

Assessment of response rates (HbA1c reduction ≥ 1% in the add-on studies and ≥ 2% in the initial combination study) in patients stratified by baseline demographic and clinical categorical covariates (sex, age, duration of diabetes, BMI, HbA1c, C-peptide AUC, insulin AUC, glucagon AUC, glucose AUC and insulin secretion) suggested only isolated correlations with response rates. The study of add-on to metformin suggested a correlation for saxagliptin 2.5 mg vs. placebo only in baseline glucose AUC (odds ratio, 1.07; p < 0.05). The study of add-on to glyburide suggested a correlation for saxagliptin 2.5 mg vs. up-titration of glyburide only among patients with BMI ≥ 30 kg/m² vs. BMI < 30 kg/m² (odds ratio, 1.39; p < 0.05). The study of add-on to a TZD showed no correlations between baseline covariates and treatment response rates. The study of saxagliptin 5 mg plus metformin as initial combination therapy in drug-naive patients suggested a correlation for saxagliptin plus metformin vs. metformin monotherapy only for baseline HbA1c (odds ratio, 3.08; p < 0.05). All other correlations between baseline covariates and treatment response in the four studies were not significant. With no consistent associations

### Table 1 Glycaemic responses at 24 weeks with saxagliptin vs. placebo as an add-on to metformin*

|Criterion for response| Treatment groups| Response rates among all assessed patients| Difference (95% CI) vs. Placebo + Metformin (Placebo + Metformin)| Response rates in patients who did not experience hypoglycaemia| Difference (95% CI) vs. Placebo + Metformin (Placebo + Metformin)|
|---|---|---|---|---|---|
|HbA1c reduction from BL ≥ 1.0%| PBO + MET (n = 179)| 18/175 (10.3) | – | 17/175 (9.7) | – |
| | SAXA 2.5 + MET (n = 192)| 62/186 (33.3) | 23.0% (14.8%, 31.2%) | 55/186 (29.6) | 19.9% (11.9%, 27.9%) |
| | SAXA 5 + MET (n = 191)| 74/186 (39.8) | 29.5% (20.9%, 37.8%) | 69/186 (37.1) | 27.4% (19.0%, 35.6%) |
|HbA1c reduction from BL ≥ 0.7%| PBO + MET (n = 179)| 38/175 (21.7) | – | 35/175 (20.0) | – |
| | SAXA 2.5 + MET (n = 192)| 85/186 (45.7) | 24.0% (14.3%, 33.3%) | 75/186 (40.3) | 20.3% (10.9%, 29.4%) |
| | SAXA 5 + MET (n = 191)| 102/187 (51.1) | 32.8% (23.1%, 42.0%) | 95/186 (51.1) | 31.1% (21.4%, 40.2%) |
|HbA1c reduction from BL ≥ 0.5%| PBO + MET (n = 179)| 47/175 (26.9) | – | 43/175 (24.6) | – |
| | SAXA 2.5 + MET (n = 192)| 105/186 (56.5) | 29.6% (19.6%, 39.1%) | 94/186 (50.5) | 26.0% (16.0%, 35.4%) |
| | SAXA 5 + MET (n = 191)| 118/187 (63.1) | 36.2% (26.3%, 45.4%) | 111/186 (59.7) | 35.1% (25.2%, 44.3%) |

BL, baseline; CI, confidence interval; HbA1c, glycated haemoglobin; MET, metformin; PBO, placebo; SAXA 2.5, SAXA 5, saxagliptin 2.5 or 5 mg once daily. n/N, number of responders/number assessed. *Metformin continued at stable dosages of 1500–2550 mg/day.
across doses or across studies with different background medications, it is likely that the cited isolated examples represent chance findings.

**Discussion**

In a prospective observational study of the UKPDS participants (4), the incidence rates for any diabetes pathology-related end-point steadily increased with every 1% increase in HbA1c level, such that there was a threefold increase in risk for diabetes complications (myocardial infarction, sudden death, angina, stroke, renal failure, lower extremity amputation or death from peripheral vascular disease, death from hyperglycaemia or hypoglycaemia, heart failure, vitreous haemorrhage, retinal photocoagulation and cataract extraction) over the HbA1c range of median values of 5.6–10.6%. Importantly, there was no HbA1c threshold at which the risk trajectory changed. Thus, meaningful reductions in HbA1c can be clinically beneficial even if the goal of maintaining HbA1c below 7% is not achieved.

The purpose of this study was to assess the ability of treatment with saxagliptin to provide reductions in HbA1c≥1% [identified as clinically consequential in the UKPDS (4)] and other large mean reductions in HbA1c in patients with T2DM, while maintaining a low incidence of hypoglycaemia. The original published reports of these studies demonstrated that mean reductions in HbA1c were significantly greater with saxagliptin than with comparators. Likewise, these post hoc analyses show significantly higher rates of large glycaemic response with saxagliptin 2.5 or 5 mg once daily vs. placebo as an add-on to another antihyperglycaemic agent (large response defined as HbA1c reduction ≥1%), and with saxagliptin 5 mg once daily plus metformin as initial combination therapy vs. metformin monotherapy in drug-naive patients (defined as HbA1c reduction ≥2%).

Although DPP-4 inhibitors have been associated with mean reductions of 0.5–0.8% in HbA1c (27), in the present analysis, HbA1c reductions ≥1% were achieved by 18–29% more patients with T2DM receiving saxagliptin 2.5 or 5 mg as an add-on to another antihyperglycaemic agent than placebo. Moreover, reductions ≥2% were achieved by 18% more drug-naive patients receiving initial combination therapy with saxagliptin 5 mg and metformin than metformin monotherapy. Among patients receiving saxagliptin and achieving these reductions without experiencing an event of hypoglycaemia, response rates were

| Table 2 Glycaemic responses at 24 weeks with saxagliptin vs. placebo as an add-on to a sulphonylurea* |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Criterion for response                           | Treatment groups                                  | Response rates among all assessed patients        | Response rates in patients who did not experience hypoglycaemia |
|                                                  |                                                   | n/N (%)                                           | n/N (%)                                           |
| HbA1c reduction from BL ≥ 1.0%                   | PBO + SU (n = 267)                                | 36/264 (13.6)                                     | 32/264 (12.1)                                     |
|                                                  | SAXA 2.5 + SU (n = 248)                           | 78/246 (31.7)                                     | 61/246 (24.8)                                     |
|                                                  | SAXA 5 + SU (n = 253)                             | 91/250 (36.4)                                     | 76/250 (30.4)                                     |
| HbA1c reduction from BL ≥ 0.7%                   | PBO + SU (n = 267)                                | 57/264 (21.6)                                     | 47/264 (17.8)                                     |
|                                                  | SAXA 2.5 + SU (n = 248)                           | 105/246 (42.7)                                    | 82/246 (33.3)                                     |
|                                                  | SAXA 5 + SU (n = 253)                             | 123/250 (49.2)                                    | 103/250 (41.2)                                    |
| HbA1c reduction from BL ≥ 0.5%                   | PBO + SU (n = 267)                                | 78/264 (29.5)                                     | 65/264 (24.6)                                     |
|                                                  | SAXA 2.5 + SU (n = 248)                           | 127/246 (51.6)                                    | 102/246 (41.5)                                    |
|                                                  | SAXA 5 + SU (n = 253)                             | 145/250 (56.8)                                    | 119/250 (47.6)                                    |
| BL, baseline; CI, confidence interval; HbA1c, glycated haemoglobin; PBO, placebo; SAXA 2.5, SAXA 5, saxagliptin 2.5 or 5 mg once daily; SU, sulphonylurea. n/N = number of responders/number assessed. *Glyburide at the following dosages: 7.5 mg/day open-label; increased to 10 mg/day at randomisation in the placebo group by addition of 2.5 mg/day as part of blinded regimen; in all groups, adjustable down to 5 mg/day in case of hypoglycaemia or up to 15 mg/day at investigator’s discretion.
Clinically relevant reductions in HbA1c with saxagliptin

13–29% higher than placebo in the add-on studies and 18% higher than metformin alone in the initial combination with metformin study.

A further objective of this analysis was to understand predictors of larger than mean glycaemic response based on baseline patient demographics, which could assist in identifying patients in whom a robust response could be expected. Unfortunately, no consistent associations across doses or across studies with different background medications were found among the principal demographic and clinical covariates employed in these studies. Given the dichotomous end-point and a relatively limited sample size for detecting interactions, the ability to detect differential treatment effects by subgroup is limited in this dataset. Larger patient populations, such as those for DPP-4 outcome studies such as SAVOR (28), may provide more power to identify subpopulations that may experience more glycaemic benefit.

Patients for whom metformin is contraindicated, such as those with renal disease or renal dysfunction because of the risk of lactic acidosis, or for whom metformin should not be initiated, such as patients ≥ 80 years of age unless adequate renal function has been demonstrated, are candidates for treatment with DPP-4 inhibitors (29). Limited conclusions can be made about saxagliptin efficacy and tolerability in these patient populations from the current analyses because in the included studies, less than 20% of patients were 65 years or older, and patients with abnormal renal function were excluded. However, in a 12-week study (30) with 40-week extension (31) in

---

**Table 3** Glycaemic responses at 24 weeks with saxagliptin vs. placebo as an add-on to a thiazolidinedione*

| Criterion for response | Treatment groups       | Response rates among all assessed patients | Response rates in patients who did not experience hypoglycaemia |
|------------------------|------------------------|--------------------------------------------|---------------------------------------------------------------|
| HbA1c reduction from BL ≥ 1.0% | PBO + T2D (n = 184) | 36/180 (20.0) | 35/180 (19.4) |
|                        | SAXA 2.5 + T2D (n = 195) | 76/192 (39.6) | 72/192 (37.5) |
|                        | SAXA 5 + T2D (n = 186) | 92/183 (50.3) | 89/183 (48.6) |
| HbA1c reduction from BL ≥ 0.7% | PBO + T2D (n = 184) | 60/180 (33.3) | 59/180 (32.8) |
|                        | SAXA 2.5 + T2D (n = 195) | 102/192 (53.1) | 97/192 (50.5) |
|                        | SAXA 5 + T2D (n = 186) | 116/183 (63.4) | 112/183 (61.2) |
| HbA1c reduction from BL ≥ 0.5% | PBO + T2D (n = 184) | 80/180 (44.4) | 78/180 (43.3) |
|                        | SAXA 2.5 + T2D (n = 195) | 117/192 (60.9) | 112/192 (58.3) |
|                        | SAXA 5 + T2D (n = 186) | 131/183 (71.6) | 127/183 (69.4) |

*Pioglitazone continued at 4 or 8 mg/day or rosiglitazone continued at 30 or 45 mg/day.

---

**Figure 1** Large glycaemic response (HbA1c reduction from baseline ≥ 1.0%)* in studies of saxagliptin as an add-on to another oral antihyperglycaemic drug. MET, metformin; SAXA 2.5, saxagliptin 2.5 mg once daily; SAXA 5, saxagliptin 5 mg once daily; SU, sulphonylurea (glyburide); T2D, thiazolidinedione (pioglitazone or rosiglitazone). *Pioglitazone continued at 4 or 8 mg/day or rosiglitazone continued at 30 or 45 mg/day.

---

© 2013 Bristol-Myers Squibb Co. International Journal of Clinical Practice published by John Wiley & Sons Ltd.

Int J Clin Pract. August 2013, 67, 8, 759–767
patients with T2DM and moderate to severe renal impairment or end-stage renal disease, saxagliptin was effective in reducing HbA1c vs. placebo (placebo-corrected, adjusted mean change from baseline –0.42% at 12 weeks and –0.73% at 52 weeks) and was generally well tolerated. Sitagliptin and linagliptin have also provided effective glycaemic control with good overall tolerability in patients with T2DM and moderate or severe renal insufficiency, with mean placebo-corrected reductions from baseline of 0.4–0.6% at 12 weeks, which were sustained up to 1 year (32,33). DPP-4 inhibitors are also effective in reducing HbA1c as monotherapy or an add-on therapy in elderly patients, with reported reductions ranging from approximately 0.5 to 1.2% (34–38). In addition, results of a meta-analysis of trials suggest that older age is a predictor of greater efficacy of DPP-4 inhibitors in T2DM (39).

Several classes of antihyperglycaemic agents can produce meaningful reductions in HbA1c, but they differ in terms of associated risk, including risk of hypoglycaemia. Sulphonylureas have a high risk for hypoglycaemia whereas DPP-4 inhibitors have a low risk (40). The combination of saxagliptin with a sulphonylurea was associated with increased reports

Table 4 Glycaemic responses at 24 weeks with saxagliptin + metformin* as initial combination therapy vs. metformin* monotherapy in drug-naive patients

| Criterion for response | Treatment groups | n/N (%) | Difference (95% CI) vs. PBO + MET | n/N (%) | Difference (95% CI) vs. PBO + MET |
|------------------------|------------------|---------|-----------------------------------|---------|-----------------------------------|
| HbA1c reduction from BL ≥ 2.5% | MET (n = 328) | 106/313 (33.9) | – | 99/313 (31.6) | – |
| | SAXA 5 + MET (n = 320) | 157/306 (51.3) | 17.4% (9.6%, 25.1%) | 151/306 (49.3) | 17.7% (10.0%, 25.2%) |
| HbA1c reduction from BL ≥ 2.0% | MET (n = 328) | 156/313 (49.8) | – | 148/313 (47.3) | – |
| | SAXA 5 + MET (n = 320) | 209/306 (68.3) | 18.5% (10.7%, 26.0%) | 201/306 (65.7) | 18.4% (10.6%, 26.0%) |
| HbA1c reduction from BL ≥ 1.5% | MET (n = 328) | 200/313 (63.9) | – | 190/313 (60.7) | – |
| | SAXA 5 + MET (n = 320) | 233/306 (76.1) | 12.2% (5.0%, 19.4%) | 223/306 (72.9) | 12.2% (4.7%, 19.5%) |
| HbA1c reduction from BL ≥ 1.0% | MET (n = 328) | 268/306 (87.6) | 9.9% (4.0%, 15.9%) | 257/306 (84.0) | 10.2% (3.8%, 16.6%) |
| | SAXA 5 + MET (n = 320) | 286/306 (93.5) | 17.8% (12.3%, 23.4%) | ND | |
| HbA1c reduction from BL ≥ 0.7% | MET (n = 328) | 256/313 (81.8) | – | ND | |
| | SAXA 5 + MET (n = 320) | 286/306 (93.5) | 17.8% (12.3%, 23.4%) | ND | |
| HbA1c reduction from BL ≥ 0.5% | MET (n = 328) | 293/306 (95.8) | 15.3% (10.5%, 20.5%) | ND | |

BL, baseline; CI, confidence interval; HbA1c, glycated haemoglobin; MET, metformin; ND, not determined; PBO, placebo; SAXA 5, saxagliptin 5 mg once daily. n/N, number of responders/number assessed. *Metformin titrated up to target dosage of 2000 mg/day.

Figure 2 Large glycaemic response (HbA1c reductions from baseline ≥ 2.0% and ≥ 2.5%)* in study of saxagliptin + metformin as initial combination therapy vs. metformin monotherapy in drug-naive patients. MET, metformin; SAXA 5, saxagliptin 5 mg once daily. n, number of patients randomised and treated. *Difference (95% CI) from metformin monotherapy shown above bars.

© 2013 Bristol-Myers Squibb Co. International Journal of Clinical Practice published by John Wiley & Sons Ltd.

Int J Clin Pract, August 2013, 67, 8, 759–767
of hypoglycaemia (15), compared with that observed with saxagliptin plus metformin combination (16). Therefore, it is not surprising that in the present post hoc analyses, the differences between overall rates of glycaemic response and rates of response without experiencing hypoglycaemia were greater in the study of saxagliptin add-on to glyburide than in the other studies (Tables 1–4), reflecting the higher incidence of hypoglycaemia associated with the sulphonylurea. It is therefore recommended that the dose of sulphonylurea be lowered when used concomitantly with saxagliptin or other DPP-4 inhibitors (26). The post hoc analyses presented here indicate that saxagliptin used as an add-on to another non-insulin antihyperglycaemic agent (except perhaps a sulphonylurea) can achieve large decreases in HbA1c with minimal risk of hypoglycaemia. This outcome may be attributable to its glucose-dependent mechanism.

Limitations of the analyses presented include the fact that they were performed post hoc, using last observations carried forward. The criteria used in this analysis to define a large reduction in HbA1c were based on general clinical expectations of what constitutes a large glycaemic response and changes in HbA1c that have been documented to reduce T2DM-related complications (4). In addition, decreases in HbA1c should always be considered in the context of baseline values in the studies; therefore, the reported outcomes may not be applicable to patients with baseline HbA1c outside the range required for study inclusion. In the saxagliptin studies, the ADA guidelines on diet and exercise were supported. It is likely (based on reductions in HbA1c with placebo) that diet and exercise compliance improved between the randomisation and primary analysis point. Finally, the analyses offer no insight into durability of the glycaemic effect assessed here.

Conclusions

Reduction in HbA1c can reduce the incidence or severity of complications related to T2DM, even if the goal of maintaining HbA1c < 7% is not achieved. The present post hoc analyses of studies of saxagliptin as an add-on therapy to another antihyperglycaemic drug and as initial combination therapy with metformin in drug-naive patients assessed the proportions of T2DM patients who achieved glycaemic responses larger than the mean reductions expected with a DPP-4 inhibitor (≥ 1.0% in the add-on studies; ≥ 1.0% to ≥ 2.5% in the initial combination study). The analyses show that the incidence of hypoglycaemia is low with saxagliptin and that the proportions of patients who achieve large glycaemic responses are significantly higher with saxagliptin than with the comparator regimens, even when patients who experience hypoglycaemia are not counted as responders.

Author contributions

All authors of this manuscript had full access to the data and participated in the concept, design and drafting of this manuscript.

Acknowledgement

The authors thank Mark Donovan, PhD, of Bristol-Myers Squibb for statistical assistance and critical review of the manuscript. Medical writing support for the preparation of this manuscript was provided by Valerie P. Zediak, PhD, and Judy Fallon, PharmD, from Complete Healthcare Communications, Inc., with funding from Bristol-Myers Squibb and AstraZeneca.

References

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
2. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.
3. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetest. N Engl J Med 2008; 359: 1577–89.
4. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12.
5. Turnbull FM, Abearza C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288–98.
6. Handelman Y, Mechanick JJ, Blonde L et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17: 1–53.
7. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–79.
8. Lee AJ. Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy 1996; 16: 327–51.
9. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005; 7: 675–91.
10. Knop FK, Holst JJ, Vildholl T. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. IDrugs 2008; 11: 497–501.
11. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941–8.
12. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–705.
13. Freeman JS. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo Clin Proc 2010; 85: 55–14.
14. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194–206.
15. Chacra AR, Tan GH, Apanovitch A et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63: 1395–406.
Clinical relevant reductions in HbA1c with saxagliptin

16 DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care* 2009; 32: 1649–55.

17 Hollander P, Li I, Allen E et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. *J Clin Endocrinol Metab* 2009; 94: 4810–9.

18 Jadzinsky M, Pfutzner A, Paz-Pacheco E et al. Saxagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. *Pharmacotherapy* 2009; 29: 555–67S.

19 DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care* 2009; 32: 1649–55.

20 Aschner P, Kipnes MS, Lunceford JK et al. Effects of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2006; 29: 2632–7.

21 Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care* 2006; 29: 2638–43.

22 Herrmanssen K, Kipnes M, Luo E et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. *Diabetes Obes Metab* 2007; 9: 733–45.

23 Rosenstock J, Brazg R, Andryuk PJ et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther* 2006; 28: 1556–68.

24 Zarowitz BJ, Conner C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. *Pharmacotherapy* 2009; 29: 555–67S.

25 Reddard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract* 2009; 15: 540–59.

26 Onglyza® (saxagliptin). Full Prescribing Information. Princeton, NJ/Wilmington, DE: Bristol-Myers Squibb/AstraZeneca Pharmaceuticals LP, 2011.

27 Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. *Am J Manag Care* 2010; 16: S187–94.

28 Scirica BM, Bhatt DL, Braunwald E et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. *Am Heart J* 2011; 162: 818–25.

29 Glucophage (metformin hydrochloride) and Glucophage XR (metformin hydrochloride extended-release). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company, 2009.

30 Nowicki M, Rychlik I, Haller H et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. *Diabetes Obes Metab* 2011; 13: 523–32.

31 Nowicki M, Rychlik I, Haller H et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. *Int J Clin Pract* 2011; 65: 1230–9.

32 Chan JG, Scott R, Arjona Ferreira JC et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. *Diabetes Obes Metab* 2008; 10: 545–55.

33 McGill JB, Sloan L, Newman J et al. Long-term efficacy and safety of li saxagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. *Diabetes Care* 2013; 36: 237–44.

34 Barzilai N, Guo H, Mahoney EM et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *Curr Med Res Opin* 2011; 27: 1049–58.

35 Doucet J, Chacra A, Maheux P et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. *Curr Med Res Opin* 2011; 27: 863–9.

36 Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. *Am J Geriatr Pharmacother* 2010; 8: 405–18.

37 Schweizer A, Depjager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabetes Obes Metab* 2009; 11: 804–12.

38 Schweizer A, Depjager S, Foley JE et al. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population >/=75 years: a pooled analysis from a database of clinical trials. *Diabetes Obes Metab* 2011; 13: 55–64.

39 Monami M, Cremasco F, Lamanna C et al. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. *Diabetes Metab Res Rev* 2011; 27: 362–72.

40 Bennett WL, Maruthur NM, Singh S et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. *Ann Intern Med* 2011; 154: 602–13.